Clinical trials: Cavernous Angioma, Familial
Cerebral Cavernous Malformation, Cavernous Angioma
Biomarkers of CASH
The project aims to develop prognostic and diagnostic blood tests for symptomatic brain hemorrhage in patients diagnosed with cavernous angiomas, a critical clinical challenge in a disease affecting more than a million Americans.
- Conditions
- Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy
- Trial name
- NCT04467489
- Testing
- observational
- Where
- 4 sites in United States
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
CCM Blood Biomarker Validation Study
Cerebral cavernous malformations (CCMs), one of the most common microvascular malformations in the capillary beds of the brain, are susceptible to hemorrhagic stroke.
- Trial name
- NCT05148663
- Testing
- CCM Hemorrhagic Panel
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Cavernous Malformation, Cerebral, Cavernous Angioma
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate…
- Conditions
- Cavernous Malformation, Cerebral, Cavernous Angioma, Cavernous Hemangioma, Cavernous Hemangioma of Brain
- Trial name
- CRESS (NCT04076449)
- Where
- 2 sites in China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- yuanli Zhao
Cerebral Cavernous Malformation
Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration
This Phase 1, dose-escalation, double-blind, multiple ascending dose (MAD) study was designed to assess the safety and tolerability of NRL-1049 compared to placebo in healthy adult participants and to determine the maximum…
- Trial name
- NCT07908134
- Testing
- NRL-1049
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.